Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: Call for consensus [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 2, 2001, Pages 210-211

  Becker, Stephen ^a   Fisher, Alvan ^b   Flexner, Charles ^c   Gerber, John G ^d   Haubrich, Richard ^e   Kashuba, Angela D M ^f   Luber, Andrew D ^g   Piscitelli, Stephen C ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g Pacific Oaks Medical Center   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0035364875     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200106010-00018     Document Type: Letter

References (11)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Once-daily indinavir plus ritonavir: Preliminary results of the PIPO study
3. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
4. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits
5. Enhancement of pharmacokinetic parameters of amprenavir when combined with low does ritonavir (APV 600 mg/RTV 100 mg bid) and preliminary efficacy results
6. A pharmacokinetic (PK) study to investigate the influence of efavirenz (EFV) on a BID indinavir (IDV)/Ritonavir (RTV) regimen (800/100 mg) in healthy volunteers
7. Ritonavir-containing dual protease inhibitor regimens may have synergistic antiviral effects in patients - Based on in vitro model
8. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine
9. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
10. Tolerability profile of amprenavir in combination with various NRTIs
11. Genotypic correlates of reduced in vitro susceptibility to ABT-378 in HIV isolates from patients failing protease inhibitor therapy